Elma Maria, Krusel Kathryn, Crumpler Megan, Tavella Nico, Talan Ali, Rendina Jonathon, Pandori Mark
Alameda County Public Health Laboratory, United States.
Orange County Public Health Laboratory, United States.
J Clin Virol. 2020 Jul;128:104422. doi: 10.1016/j.jcv.2020.104422. Epub 2020 May 6.
There is currently an absence of products which are cleared by the FDA to provide supplemental testing for oral fluid for HIV antibody. We created a procedure for the use of the BioRad Geenius HIV-1/2 as a supplemental antibody test for oral fluid specimens. The modified procedure was evaluated for its ability to detect HIV-1 antibody in oral fluid in specimens that were found to be repeatedly reactive for HIV-1 antibody by way of the Avioq HIV-1 enzyme immunoassay (EIA). Evaluated were oral fluid specimens analyzed at a local public health laboratory which were stored frozen and oral fluid specimens collected prospectively. Prospectively collected specimens were from patients whose HIV status was subsequently assessed through blood-based testing. For retrospective specimens found repeatedly EIA reactive, and positive by Western blot, the modified Geenius was found positive in 37/38 instances (97.4 %). Those specimens with a mean EIA signal-to-cutoff (S/CO) greater than 3.00 were found to be positive by Geenius in 34/34 (100 %) of instances. For specimens found repeated reactive by EIA and positive by Western blot with mean S/CO less than or equal to 3.00, the Geenius was positive in 4/5 instances (80 %) of instances. For prospectively collected specimens, the Geenius accurately confirmed infection in 22/24 cases (92 %) while prospective specimens found repeatedly reactive by EIA without supplemental Geenius testing were confirmed positive in 29/37 instances (78 %). A modified usage of the Geenius HIV-1/2 Supplemental Assay antibody test may provide utility in the supplementation of testing of oral fluid for the presence of HIV-1 antibody.
目前尚无经美国食品药品监督管理局(FDA)批准用于提供口腔液HIV抗体补充检测的产品。我们制定了一种使用伯乐公司的Geenius HIV-1/2作为口腔液标本补充抗体检测的程序。对该改良程序检测口腔液中HIV-1抗体的能力进行了评估,这些标本通过Avioq HIV-1酶免疫测定(EIA)被发现对HIV-1抗体反复呈反应性。评估的口腔液标本包括在当地公共卫生实验室分析的冷冻保存的标本以及前瞻性收集的标本。前瞻性收集的标本来自随后通过血液检测评估HIV状态的患者。对于回顾性标本,若其EIA反复呈反应性且经蛋白印迹法检测为阳性,改良后的Geenius在38例中有37例(97.4%)呈阳性。那些平均EIA信号与临界值(S/CO)大于3.00的标本,Geenius在34例中有34例(100%)呈阳性。对于EIA反复呈反应性且经蛋白印迹法检测为阳性且平均S/CO小于或等于3.00的标本,Geenius在5例中有4例(80%)呈阳性。对于前瞻性收集的标本,Geenius在24例中有22例(92%)准确确认感染,而未经Geenius补充检测但EIA反复呈反应性的前瞻性标本在37例中有29例(78%)被确认为阳性。Geenius HIV-1/2补充检测抗体试验的改良用法可能有助于补充检测口腔液中HIV-1抗体的存在情况。